Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Accounts Payable of $2.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $2.00M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $10.00K, a 99.47% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $275.00K, a 81.32% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$33.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2025 was $580.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$19.10M, a 220.27% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2023 was $15.88M, a 756.63% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.85M, a 176.72% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.01M 10-Q · filed 2026-08-06 | $2.29M derived: sum of 3 quarters · filed 2026-08-06 | $2.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $10.00K 10-Q · filed 2026-05-07 | $285.00K derived: sum of 2 quarters · filed 2026-05-07 | $252.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $242.00K derived: sum of 2 quarters · filed 2026-03-03 | -$1.29M derived: sum of 3 quarters · filed 2026-08-06 | $580.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.57M derived: sum of 2 quarters · filed 2026-08-06 | $305.00K 10-Q · filed 2025-11-06 | $1.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $338.00K 10-Q · filed 2026-08-06 | $1.81M derived: sum of 3 quarters · filed 2026-08-06 | -$1.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.87M 10-Q · filed 2026-05-07 | $3.34M derived: sum of 2 quarters · filed 2026-05-07 | -$144.00K derived: sum of 3 quarters · filed 2026-05-07 | -$16.58M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$2.02M derived: sum of 2 quarters · filed 2026-03-03 | -$18.45M derived: sum of 3 quarters · filed 2026-03-03 | -$19.10M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$19.92M derived: sum of 2 quarters · filed 2025-11-06 | -$20.57M 10-Q · filed 2025-11-06 | -$4.75M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$16.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$17.09M 10-Q · filed 2025-08-07 | -$1.27M derived: sum of 3 quarters · filed 2025-08-07 | -$19.66M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$652.00K 10-Q · filed 2025-05-08 | $15.17M derived: sum of 2 quarters · filed 2025-05-08 | -$3.23M derived: sum of 3 quarters · filed 2025-05-08 | $10.62M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $15.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$2.57M derived: sum of 2 quarters · filed 2025-03-04 | $11.27M derived: sum of 3 quarters · filed 2025-03-04 | $15.88M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$18.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$4.55M derived: sum of 2 quarters · filed 2024-11-07 | $62.00K 10-Q · filed 2024-11-07 | -$738.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $13.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $18.45M 10-Q · filed 2024-08-08 | $17.66M derived: sum of 3 quarters · filed 2024-08-08 | $16.55M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.61M 10-Q · filed 2024-05-09 | $3.81M derived: sum of 2 quarters · filed 2024-05-09 | $2.71M derived: sum of 3 quarters · filed 2024-05-09 | $1.45M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$1.90M derived: sum of 2 quarters · filed 2024-02-22 | -$3.17M derived: sum of 3 quarters · filed 2024-02-22 | $1.85M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.37M derived: sum of 2 quarters · filed 2023-11-09 | $2.65M 10-Q · filed 2023-11-09 | $4.04M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.75M 10-Q · filed 2023-08-10 | $5.14M derived: sum of 3 quarters · filed 2024-02-22 | $5.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $5.02M 10-Q · filed 2023-05-11 | $6.41M derived: sum of 2 quarters · filed 2024-02-22 | $6.56M derived: sum of 3 quarters · filed 2024-02-22 | $5.51M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.54M derived: sum of 2 quarters · filed 2024-02-22 | $493.00K derived: sum of 3 quarters · filed 2024-02-22 | $670.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$893.00K derived: sum of 2 quarters · filed 2022-11-10 | -$716.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$872.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $177.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |